Exhibit 99.1

	Dr. Reddy's Laboratories Ltd.
	8-2-337, Road No. 3, Banjara Hills
	Hyderabad – 500 034, Telangana, India

	CIN: L85195TG1984PLC004507

	Tel: + 91 40 4900 2900
	Fax: + 91 40 4900 2999
	Email: mail@drreddys.com
	Web: www.drreddys.com

May 24, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that the United States Food & Drug Administration (USFDA) completed a GMP inspection at our API manufacturing facility (CTO-5) in Miryalaguda, Telangana, India. The inspection was conducted from 19^th May, 2025 to 24^th May, 2025. We have been issued a Form 483 with 2 observations, which we will address within the stipulated timeline.

This is for your information and record.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR